Mismatch repair status and clinical outcome in endometrial cancer: a systematic review and meta-analysis.

[1]  A. Malpica,et al.  Erratum: High frequency microsatellite instability has a prognostic value in endometrial endometrioid adenocarcinoma, but only in FIGO stage 1 cases (Analytical Cellular Pathology (2010) 33:5-6 (245-255)) , 2011 .

[2]  H. Mackay,et al.  Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Labianca,et al.  DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. , 2011, Journal of the National Cancer Institute.

[4]  M. Powell,et al.  Adjuvant treatment for early-stage endometrial cancer. , 2011, Clinical obstetrics and gynecology.

[5]  A. Gadducci,et al.  The evolving role of adjuvant therapy in endometrial cancer. , 2011, Critical reviews in oncology/hematology.

[6]  S. Sporny,et al.  Immunoexpression and clinical significance of the PTEN and MLH1 proteins in endometrial carcinomas. , 2011, Polish journal of pathology : official journal of the Polish Society of Pathologists.

[7]  A. Malpica,et al.  High Frequency Microsatellite Instability Has a Prognostic Value in Endometrial Endometrioid Adenocarcinoma, But Only in FIGO Stage 1 Cases , 2010, Analytical cellular pathology.

[8]  R. Labianca,et al.  Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  H. Mackay,et al.  Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: results from studies of the NCIC Clinical Trials Group (NCIC CTG). , 2010, European journal of cancer.

[10]  C. Morrison,et al.  Mismatch repair status and outcomes after adjuvant therapy in patients with surgically staged endometrial cancer. , 2010, Gynecologic oncology.

[11]  S. Gruber,et al.  Microsatellite instability in colorectal cancer—the stable evidence , 2010, Nature Reviews Clinical Oncology.

[12]  F. Abdul-Karim,et al.  Impact of microsatellite instability (MSI) on survival in high grade endometrial carcinoma. , 2009, Gynecologic oncology.

[13]  T. Whelan,et al.  Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis , 2009, The Lancet.

[14]  E. Eisenhauer,et al.  Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Potter,et al.  The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. , 2008, Gastroenterology.

[16]  P. Goodfellow,et al.  Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  C. Morrison,et al.  Improved Survival With an Intact DNA Mismatch Repair System in Endometrial Cancer , 2006, Obstetrics and gynecology.

[18]  George L Mutter,et al.  Molecular and pathologic aspects of endometrial carcinogenesis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Perucho,et al.  The relationship between microsatellite instability and PTEN gene mutations in endometrial cancer , 2006, International journal of cancer.

[20]  H. Morreau,et al.  Diagnostic Approach and Management of Lynch Syndrome (Hereditary Nonpolyposis Colorectal Carcinoma): A Guide for Clinicians , 2006, CA: a cancer journal for clinicians.

[21]  R. Gafà,et al.  Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  A. Duval,et al.  Detection of microsatellite instability in endometrial cancer: advantages of a panel of five mononucleotide repeats over the National Cancer Institute panel of markers. , 2006, Carcinogenesis.

[23]  D. Levine,et al.  Clinicopathologic significance of defective DNA mismatch repair in endometrial carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  E. Friedman,et al.  Multipopulation analysis of polymorphisms in five mononucleotide repeats used to determine the microsatellite instability status of human tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Andreu,et al.  Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. , 2005, JAMA.

[26]  M. van Engeland,et al.  Defective mismatch repair and the development of recurrent endometrial carcinoma. , 2004, Gynecologic oncology.

[27]  Sudhir Srivastava,et al.  Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. , 2004, Journal of the National Cancer Institute.

[28]  E. Eisenhauer,et al.  The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers – a study of the National Cancer Institute of Canada Clinical Trials Group , 2004, International Journal of Gynecologic Cancer.

[29]  P. Goodfellow,et al.  Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[30]  A. Duval,et al.  Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. , 2002, Gastroenterology.

[31]  A. Cossu,et al.  Microsatellite instability and mutation analysis of candidate genes in unselected sardinian patients with endometrial carcinoma , 2002, Cancer.

[32]  D. Sargent,et al.  Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  R. Kimmig,et al.  Prognostic Relevance of hMLH1, hMSH2, and BAX Protein Expression in Endometrial Carcinoma , 2001, Modern Pathology.

[34]  Jonathan J Deeks,et al.  Systematic reviews in health care: Systematic reviews of evaluations of diagnostic and screening tests. , 2001, BMJ.

[35]  A. Berchuck,et al.  Favorable Survival Associated With Microsatellite Instability in Endometrioid Endometrial Cancers , 2001, Obstetrics and gynecology.

[36]  M. Bignami,et al.  Microsatellite instability is an independent indicator of recurrence in sporadic stage I-II endometrial adenocarcinoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Email submissions from outside the United Kingdom , 2001, BMJ : British Medical Journal.

[38]  H. Kijima,et al.  Not hMSH2 but hMLH1 is frequently silenced by hypermethylation in endometrial cancer but rarely silenced in pancreatic cancer with microsatellite instability. , 2000, International journal of oncology.

[39]  D. Schaid,et al.  Microsatellite instability and hMLH1/hMSH2 expression in young endometrial carcinoma patients: Associations with family history and histopathology , 2000, International journal of cancer.

[40]  S. Bull,et al.  Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. , 2000, The New England journal of medicine.

[41]  P. Møller,et al.  Familial endometrial cancer in female carriers of MSH6 germline mutations , 1999, Nature Genetics.

[42]  J. Palazzo,et al.  MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. , 1999, Human molecular genetics.

[43]  S Srivastava,et al.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. , 1998, Cancer research.

[44]  Manel Esteller,et al.  MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas , 1998, Oncogene.

[45]  S. Merajver,et al.  Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma. , 1996, The American journal of pathology.

[46]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[47]  Jacob Cohen.  A Coefficient of Agreement for Nominal Scales , 1960 .

[48]  P. Lara,et al.  Microsatellite instability predicts clinical outcome in radiation-treated endometrioid endometrial cancer. , 2010, International journal of radiation oncology, biology, physics.

[49]  D. Chang,et al.  The biochemical basis of microsatellite instability and abnormal immunohistochemistry and clinical behavior in Lynch Syndrome: from bench to bedside , 2007, Familial Cancer.

[50]  Soma Das,et al.  Loss of hMSH 2 and hMSH 6 Expression Is Frequent in Sporadic Endometrial Carcinomas with Microsatellite Instability : A Population-based Study 1 , 2002 .

[51]  Soma Das,et al.  Loss of hMSH2 and hMSH6 expression is frequent in sporadic endometrial carcinomas with microsatellite instability: a population-based study. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.